◎ Sugi Atlas

Atlas / Disease / Cannabis dependence

Cannabis dependence

disease
On this page

Also known as cannabis abusemarijuana dependence

Summary

Cannabis dependence (MONDO:0005689) is a disease with 7 cohort genes (152 GWAS associations across 13 studies) and 96 clinical trials. Top therapeutic interventions include atomoxetine, dronabinol, and fluoxetine.

At a glance

  • Cohort genes: 7
  • GWAS associations: 152
  • Clinical trials: 96

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecannabis dependence
Mondo IDMONDO:0005689
EFOEFO:0007191
MeSHD002189
DOIDDOID:1849, DOID:9505
ICD-10-CMF12.2
ICD-111129015467
NCITC34445
SNOMED CT37344009, 85005007
UMLSC0006870
MedGen14303
Is cancer (heuristic)no

Also known as: cannabis abuse · marijuana dependence

Data availability: 152 GWAS associations (13 studies).

Disease family

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › substance-related disorder › substance dependence › drug dependence › cannabis dependence

Related subtypes (9): barbiturate dependence, hallucinogen dependence, cocaine dependence, methamphetamine dependence, alcohol and nicotine codependence, opiate dependence, phencyclidine abuse, alcohol dependence, nicotine dependence

Genetics & variants

GWAS landscape

152 GWAS associations across 13 studies. Top hits map to 31 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs44790201e-33NCAM1?0.04
rs117114072e-23SEMA3FA
rs622507134e-17CADM2?0.03
rs23108191e-16PDE4B?0.02
rs119136341e-15TAFA5?
rs67562123e-15RPL6P5 - METAP2P1?0.02
rs78394352e-14EPHX2 - GULOP?0.03
rs4721402e-14CAMKMT - LINC01833?0.02
rs45937662e-14LINC01360?0.02
rs21326603e-14SEMA6D?0.03
rs124975694e-14USP4A0.02
rs563728217e-14GULOP?
rs15264808e-14BARHL2 - LINC02609?0.02
rs81043171e-13CACNA1A?
rs75192591e-13PDE4BA0.02
rs18236734e-13CRLF3P1 - CAPZBP1?0.02
rs131073255e-13SLC39A8T0.04
rs112108871e-12PTPRF?0.02
rs359849742e-12MCFD2P1 - ZNF184?0.04
rs37748002e-12USP4?
rs65893862e-12DRD2 - TMPRSS5T0.02
rs359264952e-12SLC38A3T
rs8648823e-12RABEPKT0.02
rs77830124e-12FOXP2A
rs26665506e-12SEMA6D?0.02
rs68005836e-12PLCL2?0.02
rs45540027e-12USP4?0.02
rs64327081e-11DPP4?0.02
rs7266102e-11CADM2T0.02
rs94677732e-11BTN1A1P1 - BTN1A1A

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90320049Levey DF202342,281843,744Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications.
GCST90320050Levey DF202319,065104,143Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications.
GCST011179Johnson EC202017,068357,219A large-scale genome-wide association study meta-analysis of cannabis use disorder.
GCST90455647Chen D202414,808343,726Unraveling shared susceptibility loci and Mendelian genetic associations linking educational attainment with multiple neuropsychiatric disorders.
GCST90320051Levey DF20232,77435,515Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications.
GCST008414Demontis D20192,38748,985Genome-wide association study implicates CHRNA2 in cannabis use disorder.
GCST008415Demontis D20192,3870Genome-wide association study implicates CHRNA2 in cannabis use disorder.
GCST005133Agrawal A20172,0806,435Genome-wide association study identifies a novel locus for cannabis dependence.
GCST000861Agrawal A20107082,346A genome-wide association study of DSM-IV cannabis dependence.
GCST90320052Levey DF20231946,649Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding1
Tier 2: splice/UTR3
Tier 3: regulatory1
Tier 4: intronic/intergenic45

MAF distribution

BucketVariants
common (>=0.05)50
low_freq (0.01-0.05)0
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant37
intergenic_variant8
regulatory_region_variant1
missense_variant1
splice_region_variant1
splice_polypyrimidine_tract_variant1
3_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs447902011112990721G>A0.05intron_variantNCAM11e-33Tier 4: intronic/intergenic
rs11711407350187596A>C,G,T0.05intron_variantSEMA3F2e-23Tier 4: intronic/intergenic
rs62250713385464643A>G,T0.05intron_variantCADM24e-17Tier 4: intronic/intergenic
rs2310819165974413C>A,T0.05intron_variantPDE4B1e-16Tier 4: intronic/intergenic
rs119136342248732047T>G0.05intron_variantTAFA51e-15Tier 4: intronic/intergenic
rs67562122145382564C>G,T0.05intergenic_variantRPL6P5 - METAP2P13e-15Tier 4: intronic/intergenic
rs7839435827555436G>A,T0.05intergenic_variantEPHX2 - GULOP2e-14Tier 4: intronic/intergenic
rs472140244912765C>T0.05regulatory_region_variantCAMKMT - LINC018332e-14Tier 3: regulatory
rs4593766173307360T>A,C0.05intron_variantLINC013602e-14Tier 4: intronic/intergenic
rs21326601547387610A>G0.05intron_variantSEMA6D3e-14Tier 4: intronic/intergenic
rs12497569349327397G>A0.44intron_variantUSP44e-14Tier 4: intronic/intergenic
rs56372821827578983G>A0.05intron_variantGULOP7e-14Tier 4: intronic/intergenic
rs1526480190744429T>A,C0.05intron_variantBARHL2 - LINC026098e-14Tier 4: intronic/intergenic
rs81043171913563053C>T0.05intron_variantCACNA1A1e-13Tier 4: intronic/intergenic
rs7519259165969060G>A0.48intron_variantPDE4B1e-13Tier 4: intronic/intergenic
rs18236732103618170T>C0.05intergenic_variantCRLF3P1 - CAPZBP14e-13Tier 4: intronic/intergenic
rs131073254102267552C>A,T0.08missense_variantSLC39A85e-13Tier 1: coding
rs11210887143610348G>A0.05intron_variantPTPRF1e-12Tier 4: intronic/intergenic
rs35984974627442643G>A0.05intergenic_variantMCFD2P1 - ZNF1842e-12Tier 4: intronic/intergenic
rs3774800349297335G>A,C,T0.05intron_variantUSP42e-12Tier 4: intronic/intergenic
rs658938611113573031C>G,T0.43intergenic_variantDRD2 - TMPRSS52e-12Tier 4: intronic/intergenic
rs35926495350218231C>T0.05splice_region_variantSLC38A32e-12Tier 2: splice/UTR
rs8648829125205830C>G,T0.3intron_variantRABEPK3e-12Tier 4: intronic/intergenic
rs77830127114476826G>A,T0.05intron_variantFOXP24e-12Tier 4: intronic/intergenic
rs26665501547625779T>C0.05intron_variantSEMA6D6e-12Tier 4: intronic/intergenic
rs6800583316810253A>G0.05intron_variantPLCL26e-12Tier 4: intronic/intergenic
rs4554002349299687C>G,T0.05intron_variantUSP47e-12Tier 4: intronic/intergenic
rs64327082162035338C>T0.05splice_polypyrimidine_tract_variantDPP41e-11Tier 2: splice/UTR
rs726610385502253C>A,G,T0.36intron_variantCADM22e-11Tier 4: intronic/intergenic
rs9467773626498198A>G0.05intron_variantBTN1A1P1 - BTN1A12e-11Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
FOXP2Orphanet:209908Isolated childhood apraxia of speech
FOXP2Orphanet:2510617q31 microdeletion syndrome
CHRNA2Orphanet:98784Sleep-related hypermotor epilepsy

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only7

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
FOXP2HGNC:13875ENSG00000128573O15409Forkhead box protein P2gwas
CHST11HGNC:17422ENSG00000171310Q9NPF2Carbohydrate sulfotransferase 11gwas
PIM3HGNC:19310ENSG00000198355Q86V86Serine/threonine-protein kinase pim-3gwas
CHRNA2HGNC:1956ENSG00000120903Q15822Neuronal acetylcholine receptor subunit alpha-2gwas
UCHL5HGNC:19678ENSG00000116750Q9Y5K5Ubiquitin carboxyl-terminal hydrolase isozyme L5gwas
ANKFN1HGNC:26766ENSG00000153930Q8N957Ankyrin repeat and fibronectin type-III domain-containing protein 1gwas
EPHX2HGNC:3402ENSG00000120915P34913Bifunctional epoxide hydrolase 2gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
FOXP2Forkhead box protein P2Transcriptional repressor that may play a role in the specification and differentiation of lung epithelium.
CHST11Carbohydrate sulfotransferase 11Catalyzes the transfer of sulfate to position 4 of the N-acetylgalactosamine (GalNAc) residue of chondroitin.
PIM3Serine/threonine-protein kinase pim-3Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation.
CHRNA2Neuronal acetylcholine receptor subunit alpha-2Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection…
UCHL5Ubiquitin carboxyl-terminal hydrolase isozyme L5Protease that specifically cleaves ‘Lys-48’-linked polyubiquitin chains.
ANKFN1Ankyrin repeat and fibronectin type-III domain-containing protein 1May play a role in neuronal function.
EPHX2Bifunctional epoxide hydrolase 2Bifunctional enzyme.

Protein-family classification

Druggable: 5 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.71

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Protease15.2×0.340
Antibody/Immunoglobulin14.2×0.340
Kinase14.0×0.340
Enzyme (other)23.4×0.340
Transcription factor11.2×0.714
Other/Unknown10.3×0.997

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
FOXP2Transcription factornoFork_head_dom, TF_fork_head_CS_2, FOXP-CC
CHST11Enzyme (other)yes2.8.2.5Sulfotransferase, Carb_sulfotrans_8-10
PIM3KinaseyesProt_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
CHRNA2Other/UnknownnoNicotinic_acetylcholine_rcpt, Neurotrans-gated_channel_TM, Neur_channel
UCHL5Proteaseyes3.4.19.12Peptidase_C12_UCH, Ubiquitinyl_hydrolase_UCH37, UCH37
ANKFN1Antibody/ImmunoglobulinyesAnkyrin_rpt, FN3_dom, Ig-like_fold
EPHX2Enzyme (other)yes3.1.3.106AB_hydrolase_1, Epox_hydrolase-like, HAD-SF_hydro_IA

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)7
unknown0

Top tissues across cohort

TissueCohort genes
buccal mucosa cell2
mucosa of paranasal sinus1
tibialis anterior1
blood1
cartilage tissue1
tibia1
olfactory segment of nasal mucosa1
skin of abdomen1
skin of leg1
cervix squamous epithelium1
gingival epithelium1
primordial germ cell in gonad1
calcaneal tendon1
cortical plate1
islet of Langerhans1
bronchial epithelial cell1
male germ line stem cell (sensu Vertebrata) in testis1
mucosa of transverse colon1
right adrenal gland1
right lobe of liver1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
FOXP2237broadmarkerbuccal mucosa cell, tibialis anterior, mucosa of paranasal sinus
CHST11243ubiquitousmarkertibia, blood, cartilage tissue
PIM3134ubiquitousmarkerolfactory segment of nasal mucosa, skin of abdomen, skin of leg
CHRNA2143tissue_specificyescervix squamous epithelium, primordial germ cell in gonad, gingival epithelium
UCHL5276ubiquitousmarkercortical plate, calcaneal tendon, islet of Langerhans
ANKFN1148tissue_specificmarkerbuccal mucosa cell, male germ line stem cell (sensu Vertebrata) in testis, bronchial epithelial cell
EPHX2206ubiquitousmarkerright lobe of liver, mucosa of transverse colon, right adrenal gland

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
EPHX24,455
UCHL53,301
FOXP22,557
PIM31,603
CHRNA2982
CHST11932
ANKFN1601

Structural data

PDB: 4 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
EPHX2P34913139
UCHL5Q9Y5K511
FOXP2O154092
CHRNA2Q158221

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
CHST11Q9NPF289.39
PIM3Q86V8685.64
ANKFN1Q8N95766.55

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 15. Enrichment computed across 7 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Biosynthesis of maresins11142.0×0.011EPHX2
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)1285.5×0.011EPHX2
Highly calcium permeable nicotinic acetylcholine receptors1253.8×0.011CHRNA2
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors1207.6×0.011CHRNA2
Presynaptic nicotinic acetylcholine receptors1190.3×0.011CHRNA2
Positive Regulation of CDH1 Gene Transcription1190.3×0.011FOXP2
Acetylcholine binding and downstream events1163.1×0.011CHRNA2
Postsynaptic nicotinic acetylcholine receptors1163.1×0.011CHRNA2
CS-GAG biosynthesis1108.8×0.015CHST11
Downregulation of TGF-beta receptor signaling181.6×0.018UCHL5
Peroxisomal protein import134.6×0.039EPHX2
UCH proteinases124.8×0.050UCHL5
Neurotransmitter receptors and postsynaptic signal transmission120.0×0.056CHRNA2
Transmission across Chemical Synapses115.2×0.069CHRNA2
Neuronal System18.8×0.108CHRNA2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
caudate nucleus development12407.4×0.006FOXP2
putamen development12407.4×0.006FOXP2
polysaccharide localization12407.4×0.006CHST11
stilbene catabolic process12407.4×0.006EPHX2
regulation of establishment of bipolar cell polarity12407.4×0.006ANKFN1
modulation of inhibitory postsynaptic potential12407.4×0.006CHRNA2
post-embryonic development258.7×0.006FOXP2, CHST11
epoxide metabolic process1802.5×0.013EPHX2
epithelial cell proliferation involved in lung morphogenesis1481.5×0.020FOXP2
equilibrioception1343.9×0.021ANKFN1
positive regulation of epithelial cell proliferation involved in lung morphogenesis1343.9×0.021FOXP2
vocal learning1300.9×0.021FOXP2
cellular response to nicotine1300.9×0.021CHRNA2
righting reflex1267.5×0.021FOXP2
embryonic viscerocranium morphogenesis1240.7×0.021CHST11
negative regulation of insulin secretion involved in cellular response to glucose stimulus1240.7×0.021PIM3
carbohydrate biosynthetic process1218.9×0.021CHST11
forebrain morphogenesis1200.6×0.021UCHL5
lateral ventricle development1185.2×0.021UCHL5
regulation of cholesterol metabolic process1160.5×0.021EPHX2
cellular response to forskolin1160.5×0.021PIM3
positive regulation of telomere maintenance in response to DNA damage1160.5×0.021UCHL5
cerebellar Purkinje cell differentiation1150.5×0.021FOXP2
locomotor rhythm1150.5×0.021ANKFN1
phospholipid dephosphorylation1150.5×0.021EPHX2
smooth muscle tissue development1150.5×0.021FOXP2
regulation of DNA strand elongation1150.5×0.021UCHL5
chondrocyte development1133.8×0.022CHST11
regulation of chromosome organization1133.8×0.022UCHL5
vocalization behavior1126.7×0.022FOXP2

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

28 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
AcetylcysteinePhase 3
CannabinolPhase 3
NicotinePhase 3
AprepitantPhase 2
AtomoxetinePhase 2
BaclofenPhase 2
BupropionPhase 2
BuspironePhase 2
CannabidiolPhase 2
CiticolinePhase 2
ClonazepamPhase 2
ClonidinePhase 2
DronabinolPhase 2
FluoxetinePhase 2
GabapentinPhase 2
GuanfacinePhase 2
LofexidinePhase 2
NabilonePhase 2
NabiximolsPhase 2
NaltrexonePhase 2
NefazodonePhase 2
Pregnenolone SuccinatePhase 2
ProgesteronePhase 2
PsilocybinPhase 2
QuetiapinePhase 2
TopiramatePhase 2
VareniclinePhase 2
VilazodonePhase 2

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 4 · Undrugged: 3

Druggability breadth: 4 of 7 evidence-associated genes (57%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
PIM3RUCAPARIB
CHRNA2VARENICLINE
EPHX2OXAPROZIN

Top cohort targets by molecule count

SymbolMoleculesMax phase
PIM3244
EPHX2194
CHRNA244
UCHL512
FOXP200
CHST1100
ANKFN100

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
RUCAPARIB4PIM3
SUNITINIB4PIM3
MIDOSTAURIN4PIM3
GEFITINIB4PIM3
LEFLUNOMIDE4PIM3
VARENICLINE4CHRNA2
MECAMYLAMINE4CHRNA2
NICOTINE4CHRNA2
OXAPROZIN4EPHX2
SORAFENIB4EPHX2
FULVESTRANT4EPHX2
REGORAFENIB4EPHX2
ZAFIRLUKAST4EPHX2
ZILEUTON4EPHX2
MASITINIB3PIM3
ENZASTAURIN3PIM3
ALVOCIDIB3PIM3
ALISERTIB3PIM3
LESTAURTINIB3PIM3
RUBOXISTAURIN3PIM3
RUTIN3EPHX2
SODIUM LAURYL SULFATE3EPHX2
QUERCETIN3EPHX2
EBSELEN3EPHX2
SU-0148132PIM3
CENISERTIB2PIM3
LY-20903142PIM3
NUVISERTIB2PIM3
DAPOLSERTIB2PIM3
R-4062PIM3

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
PIM3450Binding:419, Functional:30, Toxicity:1
EPHX2314Binding:311, ADMET:3
CHRNA240Binding:37, Functional:2, ADMET:1
UCHL531Binding:31

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
CHST112.8.2.5chondroitin 4-sulfotransferase
UCHL53.4.19.12ubiquitinyl hydrolase 1
EPHX23.1.3.106, 3.3.2.102-lysophosphatidate phosphatase, soluble epoxide hydrolase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
PIM3450
EPHX2314

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

28 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
RUCAPARIB4PIM3
SUNITINIB4PIM3
MIDOSTAURIN4PIM3
GEFITINIB4PIM3
LEFLUNOMIDE4PIM3
MECAMYLAMINE4CHRNA2
OXAPROZIN4EPHX2
SORAFENIB4EPHX2
FULVESTRANT4EPHX2
REGORAFENIB4EPHX2
ZAFIRLUKAST4EPHX2
ZILEUTON4EPHX2
MASITINIB3PIM3
ENZASTAURIN3PIM3
ALVOCIDIB3PIM3
ALISERTIB3PIM3
LESTAURTINIB3PIM3
RUBOXISTAURIN3PIM3
RUTIN3EPHX2
SODIUM LAURYL SULFATE3EPHX2
QUERCETIN3EPHX2
EBSELEN3EPHX2
SU-0148132PIM3
CENISERTIB2PIM3
LY-20903142PIM3
NUVISERTIB2PIM3
DAPOLSERTIB2PIM3
R-4062PIM3

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)3PIM3, CHRNA2, EPHX2
BPhased (≥1) drug, not yet approved1UCHL5
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug2CHST11, ANKFN1
EDifficult family or no structure, no drug1FOXP2

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
FOXP20—
CHST110—
ANKFN10—

Clinical trials & evidence

Clinical trials

Clinical trials: 96.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified42
PHASE226
PHASE110
PHASE49
PHASE2/PHASE34
PHASE32
PHASE1/PHASE22
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00498550PHASE4COMPLETEDTreatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
NCT00687609PHASE4TERMINATEDPilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
NCT00875836PHASE4COMPLETEDBuspirone Treatment for Marijuana Dependence
NCT01153490PHASE4COMPLETEDImproving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine
NCT01400243PHASE4COMPLETEDNicotine Patch for Marijuana Withdrawal
NCT01639872PHASE4COMPLETEDClozapine for Cannabis Use in Schizophrenia
NCT03221231PHASE4UNKNOWNN-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
NCT04595318PHASE4COMPLETEDVarenicline for Co-occurring Cannabis and Tobacco Use
NCT04721353PHASE4COMPLETEDReducing Cannabis Overuse With Prazosin
NCT00484367PHASE2/PHASE3UNKNOWNA Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers
NCT01020019PHASE2/PHASE3COMPLETEDCombined Pharmacotherapy for Cannabis Dependency
NCT01347762PHASE2/PHASE3COMPLETEDNabilone for Cannabis Dependence: A Pilot Study
NCT01598896PHASE2/PHASE3TERMINATEDCombination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
NCT01675661PHASE3COMPLETEDAchieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment
NCT02955329PHASE3COMPLETEDVaping THC From Electronic Cigarettes
NCT07523633PHASE2RECRUITINGEffect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
NCT00114439PHASE2COMPLETEDLithium Cannabis Withdrawal Study
NCT00149643PHASE2COMPLETEDEffectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
NCT00167297PHASE2COMPLETEDAtomoxetine for the Treatment of Cannabis Dependence
NCT00350285PHASE2COMPLETEDThe Teen Marijuana Check-Up
NCT00350649PHASE2COMPLETEDMaximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management
NCT00373295PHASE2COMPLETEDEffect of Baclofen on Marijuana Withdrawal and Relapse
NCT00373503PHASE2COMPLETEDEffect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse
NCT00374127PHASE2COMPLETEDComparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper
NCT00395044PHASE2COMPLETEDGabapentin Treatment of Cannabis Dependence
NCT00480441PHASE2COMPLETEDEffectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
NCT00542750PHASE1/PHASE2COMPLETEDAn Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents
NCT00656487PHASE2COMPLETEDClinical and Neurobiological Effects of Cannabis Dependence in Young Adults
NCT00954681PHASE2COMPLETEDStudy of Quetiapine Treatment for Cannabis Dependence
NCT00974376PHASE2COMPLETEDGabapentin Treatment of Cannabis Dependence
NCT01005810PHASE2COMPLETEDA Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana
NCT01110434PHASE2COMPLETEDBiobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents
NCT01292642PHASE2COMPLETEDCognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence
NCT01439828PHASE2TERMINATEDClinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal
NCT01574183PHASE2COMPLETEDVilazodone Treatment for Marijuana Dependence
NCT01611948PHASE2COMPLETEDTreatment for Cannabis Withdrawal and Dependence
NCT01618656PHASE2COMPLETEDSafety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
NCT01697709PHASE2COMPLETEDQuetiapine Pharmacotherapy for Cannabis Dependence
NCT01747850PHASE2COMPLETEDSativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence
NCT02011516PHASE2COMPLETEDBaclofen Effects on Marijuana Dependence

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
ATOMOXETINE46
DRONABINOL46
FLUOXETINE43
GUANFACINE43
VILAZODONE43
ACETYLCYSTEINE42
APREPITANT42
BACLOFEN42
CLONIDINE42
CLOZAPINE42
LOFEXIDINE42
VARENICLINE42
BUSPIRONE41
ESZOPICLONE41
LITHIUM CARBONATE41
NABILONE41
NICOTINE41
PRAZOSIN HYDROCHLORIDE41
RAMELTEON41
RIMONABANT41
RISPERIDONE41
ZOLPIDEM41
ZOPICLONE41
NABIXIMOLS32
PREGNENOLONE SUCCINATE31
REDAFAMDASTAT21
PREGNENOLONE11
CHEMBL543550003

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 73

This page pulls from 73 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot